About us

Our leadership team has experience in managing both small and large public and private companies through various stages of growth and financing strategies (venture capital, M&A transactions, IPOs, PIPEs).

They successfully sold the surface modification business of Interface Biologics to Evonik (ETR:EVK) in 2019 and founded Ripple Therapeutics in January of 2020.

Ripple Therapeutics

Ripple Therapeutics is a clinical stage company focused on improving ophthalmic therapeutics with controllable, sustained drug delivery.

Ripple’s first product – IBE-814 IVT – is an patented intravitreal Dexamethasone prodrug implant targeting diabetic macular edema (DME) and retinal vein occlusion (RVO) with a 6-9 month duration. The FDA has agreed to a 505(b)2 path for IBE-814 IVT and a Phase 2 trial is underway

To learn more about the RIPPLE-1 clinical trial,

Click here

In addition to early clinical success, we also have commercial traction for IBE-814 IVT with a licensing deal for our first product with Laboratoires Théa for North America and Europe. See announcement:

Ripple’s second product – RTC-1119 – is a patented intracameral Latanoprost prodrug implant targeting open angle glaucoma and ocular hypertension with a reliable and repeatable 6-12 month duration. We have compelling preclinical data and the FDA has agreed to a 505(b)2 path which simplifies our clinical and regulatory path.

Ripple has raised over $25 million in its seed and Series A Rounds. We are in the process of raising a Series B round which we are looking to close by the end of December 2022.